1 / 14

A QI Project to Improve Pain Management in Sickle Cell Vaso -Occlusive Crisis

A QI Project to Improve Pain Management in Sickle Cell Vaso -Occlusive Crisis. Dana LeBlanc, MD, Renee Gardner, MD, Maria Velez, MD, Cori Morrison, MD Pediatric Hematology/Oncology and Hematopoietic Stem Cell Transplant LSUHSC/Children’s Hospital of New Orleans . Background.

ehren
Download Presentation

A QI Project to Improve Pain Management in Sickle Cell Vaso -Occlusive Crisis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. A QI Project to Improve Pain Management in Sickle Cell Vaso-Occlusive Crisis Dana LeBlanc, MD, Renee Gardner, MD, Maria Velez, MD, Cori Morrison, MD Pediatric Hematology/Oncology and Hematopoietic Stem Cell Transplant LSUHSC/Children’s Hospital of New Orleans

  2. Background • Sickle Cell Disease (SCD) affects 70,000 -100,000 Americans • 2,000 infants are born with SCD each year • Pain due to vaso-occlusive crises (VOC) is a leading cause of hospital admission and healthcare cost in pediatric patients with SCD • National Hospital Ambulatory Medical Care Survey • 1999-2007: ~200,000 ED visits/yr for SCD • 78% of visits were for pain • 17% of patients 0-19 yrs of age

  3. Background • Lack of consistent healthcare provider education regarding management of these patients often results in delayed or inadequate analgesic administration • Prolongs hospital stays • Leads to patient distrust and dissatisfaction with the medical team

  4. Pathogenesis • Nucleotide substitution in the beta globin gene (glutamic acid to valine) allows hemoglobin S polymerize in deoxygenated states

  5. Treatment of VOC • IV hydration • Parenteral opioid administration • Morphine or Dilaudid • Patient controlled analgesia (PCA) or on demand boluses • Adjuvant therapies • NSAIDs • Tricyclic antidepressants

  6. Objectives • To evaluate and improve physician education, attitudes and comfort level regarding management of SCD VOC • To improve the timeliness of achieving adequate pain control during a VOC • To reduce hospital stay duration, reduce readmission rates, and improve patient satisfaction with VOC management • Ultimately, to improve the overall quality of life of our sickle cell patients

  7. Study Design • 3 parts: • Physician Education and Surveys • Patient Surveys • Inpatient Data Analysis

  8. Physician Education & Surveys • Educational modules • Grand rounds presentation • Interactive pain management workshop as part of the intern lecture series • Video recorded “refresher” prior to starting Hematology service month • Materials • Preprinted VOC order forms • Pocket cards with pain management guidelines • Pre and post education surveys • Assess resident knowledge and understanding of VOC management • Assess resident attitudes regarding SCD patients and VOC

  9. Preprinted Orders for VOC

  10. Study Tools

  11. Patient Surveys • Will survey patients both prior to and after initiation of physician education • Will assess: • Patient satisfaction with medical care received • Confidence in the medical staff • Patient perception of pain management • Preferred medications • Promptness of administration • Physician attitudes • Patients to be surveyed at routine clinic visits

  12. Inpatient Data Analysis • Retrospective chart review of SCD patients admitted for pain crises • Data to be collected: • Number of hospital days • Time until optimal pain control is achieved • Method of narcotic administration and maximum dose required • Adjuvant therapies • Readmission rates • Pre and post survey data will be analyzed

  13. Anticipated Results

  14. Questions?

More Related